Browsing Tag: Bristol Myers Squibb Launches Kopozgo® (Mavacamten) in India for the treatment of symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Mumbai, India, October13, 2025 – Bristol Myers Squibb (BMS) today announced the launch of Kopozgo® (Mavacamten) in India. Kopozgo is the first and only oral, selective cardiac myosin inhibitor approve...